ROUNDUP

Defendants: Bayer

GENERAL BACKGROUND

In July 2015, the International Agency for Research on Cancer (IARC), a specialized intergovernmental agency of the World Health Organization (WHO), issued a final health assessment of glyphosate the active chemical in Monsanto Company’s Roundup® herbicide determining that glyphosate is a Group 2A agent, “probably carcinogenic to humans.” IARC specifically linked exposure to Roundup® to non-Hodgkin lymphoma (NHL), (including its various subtypes such as lymphocytic lymphoma / chronic lymphocytic leukemia, B-cell lymphoma, hairy cell leukemia, and others.

QUALIFYING INJURIES

  • Non-Hodgkin’s Lymphoma
  • B or T-Cell Lymphoma
  • Chronic Lymphocytic Leukemia
  • Hairy Cell Lymphoma
  • Mantle Cell Lymphoma

CRITERIA

  • PC must have been diagnosed with Non- Hodgkin’s Lymphoma, B or T-Cell Lymphoma, Chronic Lymphocyte Leukemia, Hairy Cell Lymphoma, or Mantle Cell Lymphoma
  • PC must have been exposed to Roundup up in 1990 or later
  • PC must have used product for at least 1 year
  • PC must have been diagnosed at least 3 years after first use of Roundup
  • PC must be diagnosed in 2000 or later
  • PC must have been 14-75 at time of diagnosis
  • PC must be 75 or younger at sign up
  • PC must not have any of the following prior to NHL diagnosis:
  • HIV or AIDS diagnosis, Hep B or C diagnosis, Agent Orange exposure, Organ transplant recipient, Prior chemotherapy (prior to use of products)
  • PC must not currently be represented by an attorney
  • If deceased, death must be within 10 years